S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
S&P 500   4,008.01
DOW   32,223.42
QQQ   298.44
NYSE:RMD

ResMed (RMD) Stock Forecast, Price & News

$196.91
+0.05 (+0.03%)
(As of 05/16/2022 04:00 PM ET)
Add
Compare
Today's Range
$195.02
$198.79
50-Day Range
$191.46
$261.47
52-Week Range
$189.40
$301.34
Volume
346,371 shs
Average Volume
597,106 shs
Market Capitalization
$28.80 billion
P/E Ratio
37.08
Dividend Yield
0.85%
Beta
0.45
30 days | 90 days | 365 days | Advanced Chart
Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.

ResMed logo

About ResMed

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; and connectivity module and propeller solutions. In addition, it offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice agencies, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
CUSIP
76115210
Employees
7,970
Year Founded
1989

Sales & Book Value

Annual Sales
$3.20 billion
Cash Flow
$6.68 per share
Book Value
$22.41 per share

Profitability

Net Income
$474.51 million
Pretax Margin
27.17%

Debt

Price-To-Earnings

Miscellaneous

Free Float
144,208,000
Market Cap
$28.80 billion
Optionable
Optionable

Company Calendar

Ex-Dividend for 3/17 Dividend
2/09/2022
Dividend Payable
3/17/2022
Last Earnings
4/28/2022
Ex-Dividend for 6/16 Dividend
5/11/2022
Today
5/16/2022
Dividend Payable
6/16/2022
Fiscal Year End
6/30/2022
Next Earnings (Estimated)
8/04/2022

Social Links


MarketRank

Overall MarketRank

2.57 out of 5 stars

Medical Sector

96th out of 1,423 stocks

Surgical & Medical Instruments Industry

10th out of 138 stocks

Analyst Opinion: 3.3Community Rank: 3.5Dividend Strength: 1.7Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -













ResMed (NYSE:RMD) Frequently Asked Questions

Is ResMed a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ResMed stock.
View analyst ratings for ResMed
or view top-rated stocks.

Are investors shorting ResMed?

ResMed saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 1,230,000 shares, an increase of 27.8% from the March 15th total of 962,200 shares. Based on an average daily trading volume, of 611,700 shares, the days-to-cover ratio is currently 2.0 days. Approximately 0.9% of the shares of the company are sold short.
View ResMed's Short Interest
.

When is ResMed's next earnings date?

ResMed is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for ResMed
.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) released its quarterly earnings results on Thursday, April, 28th. The medical equipment provider reported $1.32 EPS for the quarter, missing the consensus estimate of $1.44 by $0.12. The medical equipment provider had revenue of $864.50 million for the quarter, compared to the consensus estimate of $900.03 million. ResMed had a net margin of 22.02% and a trailing twelve-month return on equity of 26.91%. ResMed's revenue was up 12.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.30 earnings per share.
View ResMed's earnings history
.

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, April 28th. Stockholders of record on Thursday, May 12th will be given a dividend of $0.42 per share on Thursday, June 16th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date of this dividend is Wednesday, May 11th.
View ResMed's dividend history
.

Is ResMed a good dividend stock?

ResMed pays an annual dividend of $1.68 per share and currently has a dividend yield of 0.85%. ResMed does not yet have a strong track record of dividend growth. The dividend payout ratio of ResMed is 31.64%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, ResMed will have a dividend payout ratio of 25.30% next year. This indicates that ResMed will be able to sustain or increase its dividend.
View ResMed's dividend history.

What price target have analysts set for RMD?

12 brokers have issued 1 year target prices for ResMed's stock. Their forecasts range from $240.00 to $280.00. On average, they anticipate ResMed's share price to reach $262.25 in the next twelve months. This suggests a possible upside of 33.2% from the stock's current price.
View analysts' price targets for ResMed
or view top-rated stocks among Wall Street analysts.

Who are ResMed's key executives?
ResMed's management team includes the following people:
  • Dr. Peter C. Farrell A.M., AM, B.E., BE (Hons), Ph.D., ScD, Founder & Non-Exec. Chairman (Age 80, Pay $441.46k)
  • Mr. Michael J. Farrell BE, MBA, SM, CEO & Director (Age 50, Pay $2.69M) (LinkedIn Profile)
  • Mr. Robert A. Douglas, Pres & COO (Age 62, Pay $1.94M)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 55, Pay $1.01M)
  • Dr. James R. Hollingshead Ph.D., Pres of Sleep & Respiratory Care Bus. (Age 59, Pay $1.43M)
  • Ms. Urvashi Tyagi, Chief Technology Officer
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Corp. Sec. (Age 63) (LinkedIn Profile)
  • Ms. Constance C. Bienfait, Director of Investor Relations
  • Ms. Amy Wakeham, VP of Investor Relations & Corp. Communications
  • Ms. Nupur Bhushan, Chief People Officer
What is Mick Farrell's approval rating as ResMed's CEO?

284 employees have rated ResMed CEO Mick Farrell on Glassdoor.com. Mick Farrell has an approval rating of 92% among ResMed's employees. This puts Mick Farrell in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE), Visa (V), Alibaba Group (BABA), PayPal (PYPL) and QUALCOMM (QCOM).

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.85%), BlackRock Inc. (9.13%), WCM Investment Management LLC (5.89%), State Street Corp (4.44%), Northern Trust Corp (1.49%) and Invesco Ltd. (1.20%). Company insiders that own ResMed stock include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Justin Leong, Michael J Farrell, Rajwant Sodhi, Robert Andrew Douglas and Ronald R Taylor.
View institutional ownership trends for ResMed
.

Which institutional investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including WCM Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., Arrowstreet Capital Limited Partnership, Los Angeles Capital Management LLC, UBS Group AG, First Trust Advisors LP, Canada Pension Plan Investment Board, and Northern Trust Corp. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, Carol Burt, Dave Michaud, David Pendarvis, James Hollingshead, Michael J Farrell, Rajwant Sodhi, and Robert Andrew Douglas.
View insider buying and selling activity for ResMed
or view top insider-selling stocks.

Which institutional investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., BlackRock Inc., Vanguard Group Inc., Ownership Capital B.V., Achmea Investment Management B.V., Eagle Asset Management Inc., Bridgewater Associates LP, and Swiss National Bank.
View insider buying and selling activity for ResMed
or or view top insider-buying stocks.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $196.91.

How much money does ResMed make?

ResMed has a market capitalization of $28.80 billion and generates $3.20 billion in revenue each year. The medical equipment provider earns $474.51 million in net income (profit) each year or $5.309990 on an earnings per share basis.

How many employees does ResMed have?

ResMed employs 7,970 workers across the globe.

When was ResMed founded?

ResMed was founded in 1989.

What is ResMed's official website?

The official website for ResMed is www.resmed.com.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at (858) 836-5000, via email at [email protected], or via fax at 858-836-5501.

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.